The Breast-Implant Controversy

Garry S. Brody, Frank B. Vasey, Mitchel J. Seleznick, Bernard F. Germain, Barry Meisenberg, William D. Dupont, Jan J. Van Wingerden, Ruth B. Merkatz, Jack C. Fisher, David A. Kessler, Marcia Angell

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: Dr. Angell's editorial (June 18 issue)1 on the breast-implant controversy refreshingly highlights the forgotten half of the risk-benefit ratio: efficacy. As Dr. Kessler points out in the same issue,2 the 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act require evidence of both safety and efficacy on the basis of which the Food and Drug Administration is to make a risk-benefit assessment. So much attention has been given to the risks, known and unknown (no matter how unlikely), that the benefits have been minimized. In the past year and a half, the media and consumer…

Original languageEnglish (US)
Pages (from-to)732-735
Number of pages4
JournalNew England Journal of Medicine
Volume328
Issue number10
DOIs
StatePublished - Mar 11 1993
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The Breast-Implant Controversy'. Together they form a unique fingerprint.

Cite this